Is 'dosing-to-cure' appropriate in the face of antimicrobial resistance?

Reviews and Research in Medical Microbiology

Volumn 15, Issue 2, 2004, Pages 73-80

  Drlica, Karl ^a   Zhao, Xilin ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Mutant enrichment; Mutant prevention concentration; Mutant selection window

Indexed keywords

CEFOTAXIME; ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE;

ANTIBIOTIC RESISTANCE; BACTERIUM MUTANT; DRUG DOSE REGIMEN; HOST RESISTANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW;

EID: 3442875254     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.revmedmi.0000131425.36224.59     Document Type: Review

References (67)

1. Livermore D. Bacterial resistance; origins, epidemiology, and impact. Clin Inf Dis 2003, 36:S11-S23.
2. Pechere J-C. Patients' interviews and misuse of antibiotics. Clin Inf Dis 2001, 33 (Suppl 3):S170-S173.
3. Carey B, Cryan B. Antibiotic misuse in the community - a contributor to resistance? Irish Med. J 2003, 96:43-45.
4. Drusano G, Preston S, Owens R, Ambrose P. Fluoroquinolone pharmacodynamics. Clin Inf Dis 2001, 33:2091-2092.
5. Negri M-C, Lipsitch M, Blazquez J, Levin BR, Baquero F. Concentration-dependent selection of small phenotypic differences in TEM b-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 2000, 44:2485-2491.
6. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Inf Dis 2001, 33 (Suppl 3):S147-S156.
7. Mamber S, Kolek B, Brookshire K, Bonner D, Fung-Tomc J. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob Agents Chemother 1993, 37:213-217.
8. Riesenfeld C, Everett M, Piddock L, Hall B. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob Agents Chemother 1997, 41:2059-2060.
9. Hall M, Blok H, Donders A, Paauw A, Fluit A, Verhoef J. Multidrug resistance among enterobacteriaceae is strongly associated with the presence of integrons and is independent of species or isolate origin. J Infect Dis 2003, 187:251-259.
10. Paulsen I, Banerjei L, Myers G, Nelson K, Seshadri R, Read T et al. (2003) Role of mobile DNA in the evolution of vancomycin-resistant Entercoccus faecalis. Science 299:2071-2074.
11. Hinnebusch BJ, Rosso M, Schwan T, Carniel E. High-frequency conjugative transfer of antibiotic resistance genes to Yersinia pestis in the flea midgut. Mol Microbiol 2002, 46:349-354.
12. Leverstein-van Hall M, Box A, Blok H, Paauw A, Fluit A, Verhoef J. Evidence of extensive interspecies transfer of integron-mediated antimicrobial resistance genes among multidrug-resistant enterobacteriaceae in a clinical setting. J Infect Dis 2002, 186:49-56.
13. Kruse H, Sorum H. Transfer of multiple drug resistance plasmids between bacteria of diverse origins in natural microenvironments. Appl Environ Microbiol 1994, 60:4015-4021.
14. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. J Infect Dis 2002, 185:561-565.
15. Dong Y, Zhao X, Kreiswirth B, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44:2581-2584.
16. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resistance Updates 2001, 4:93-105.
17. Bast D, Low D, Duncan C, Kilburn L, Mandell L, Davidson R, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux on levels of resistance. Antimicrob Agents Chemother 2000, 44:3049-3054.
18. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002, 46:522-524.
19. Zhanel G, Walkty A, Nichol K, Smith H, Noreddin A, Hoban D. Molecular characterization of fluoroquinolone resistant Streptooccus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003, 45:63-67.
20. Rastogi N, Ross B, Dwyer B, Goh K, Clavel-Seres S, Jeantils V, et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1992, 11:901-907.
21. Davidson R, Cavalcanti R, Brunton J, Bast DJ, deAzavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002, 346:747-750.
22. Ho PL, Tse WS, Tsang K, Kwok T, Ng T, Cheng V, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Inf Dis 2001, 32: 701-707.
23. Toubes E, Singh K, Yin D, Lyu R, Glick N, Russell L, et al. Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Inf Dis 2003, 36:724-730.
24. Ferdinand S, Sola C, Verdol B, Legrand E, Goh K, Berchel M, et al. Molecular characterization and drug resistance patterns of strains of Mycobacterium tuberculosis isolated from patients in an AIDS counseling center in Port-au-Prince, Haiti: a 1-year study. Antimicrob Agents Chemother 2003, 47:694-702.
25. Campagnolo E, Johnson K, Karpati A, Rubin C, Kolpin D, Meyer M, et al. Antimicrobial residues in animal waste and water resources proximal to large-scale swine and poultry feeding operations. Sci Total Environ 2002, 299:89-95.
26. Graslund S, Holmstrom K, Wahlstrom A. A field survey of chemicals and biological products used in shrimp farming. Marine Pollution Bulletin 2003, 46:81-90.
27. Timoney J, Linton A. Experimental ecologic studies on H2 plasmids in the intestine and faeces of the calf. J Appl Bacteriol 1982, 52:417-424.
28. deGalan B, vanTilburg P, Sluijter M, Mol S, deGroot R, Hermans P, et al. Hospital-related outbreak of infection with multidrug-resistant Streptococcus pneumoniae in The Netherlands. J Hosp Infect 1999, 42:185-192.
29. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999, 353:1843-1847.
30. The Tuberculosis Trials Consortium Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulumonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002, 360:528-534.
31. Safdar A, Chaturvedi V, Koll B, Larone D, Perlin DS, et al. Prospective, multicenter surveillance study of Candida glabrata: fluconazole an ditraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida susceptibility trends study, 1998 to 1999). Antimicrob Agents Chemother 2002, 46:3268-3272.
32. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 1997, 94:13991-13996.
33. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth, survival, and resistance. Antimicrob Agents Chemother 1998, 42:2978-2984.
34. Zhao X, Wang J-Y, Xu C, Dong Y, Zhou J, Domagala J, et al. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother 1998, 42:956-958.
35. Zhao B-Y, Pine R, Domagala J, Drlica K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C8-methoxyl group on survival in liquid media and in human macrophages, Antimicrob Agents Chemother 1999, 43:661-666.
36. Hane MW, Wood TH. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol 1969, 99:238-241.
37. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43:1756-1758.
38. Sieradzki K, Roberts R, Haber S, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999, 340: 517-523.
39. Zhou J-F, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, et al. Selection of antibiotic resistance: allelic diversity among fluoroquinolone-resistant mutations. J Inf Dis 2000, 182:517-525.
40. Sindelar G, Zhao X, Liew A, Dong Y, Zhou J, Domagala J, et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000, 44:3337-3343.
41. Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin, and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 2003, 52:61-64.
42. Firsov A, Vostrov S, Lubenko I, Drlica K, Portnoy Y, Zinner S. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis: four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:1604-1613.
43. Zinner S, Lubenko I, Gilbert D, Simmons K, Zhao X, Drlica K, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentration in and out of the mutant selection window: related changes in susceptibility, resistance frequency, and bacterial killing. J Antimicrob Chemother 2003, 52:616-622.
44. Ambrose P, Zoe-Powers A, Russo R, Jones D, Owens R. Utilizing pharmacodynamics and pharmacoeconomics in clinical and formulary decision making. In Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Edited by Nightingale C, Murakawa T, Ambrose P. New York: Marcel Dekker; 2002: 385-409.
45. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Inf Dis 2001, 32 (Suppl. 1):S39-S46.
46. N.C.f.C.L.S. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In Approved Standard M7-A4. Villanova, PA: N.C.f.C.L.S, 1997:section 5.3.4.
47. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone Bay y 3118. Clin Inf Dis 2001, 32 (Suppl 1):S16-S22.
48. Negri M, Morosini M, Baquero M, delCampo R, Blazquez J, Baquero F. Very low cefotaxime concentrations select for hypermutable Streptococcus pneumoniae populations. Antimicrob Agents Chemother 2002, 46:528-530.
49. Tillotson G, Zhao X, Drlica K. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Inf Dis 2001, 1:145-146.
50. Thomas J, Forrest A, Bhavnani S, Hyatt J, Cheng A, Ballow C, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42: 521-527.
51. Heffelfinger J, Dowell S, Jorgensen J, Klugman K, Mabry L, Musher D, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 160:1399-1408.
52. Dong J, Walker J, Nitiss J. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J Biol Chem 2000, 275:7980-7987.
53. Hansen G, Metzler K, Drlica K, Blondeau JM. Mutant prevention concentration for gemifloxacin with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003, 47:440-441.
54. Ambrose P, Grasela D. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmcodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000, 38:151-157.
55. Drusano G, Preston S, Hardalo C, Hare R, Banfield C, Andes D, et al. Use of preclinical data for selection of a phase 1/11 dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001, 45:13-22.
56. Drabu Y, Blakemore P. Comparative post-antibiotic effect of five antibiotics against ten aerobic gram-positive cocci. Drugs Exp Clin Res 1990, 16:557-563.
57. Zhanel G, Craig W. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet 1994, 27:377-392.
58. Mitchison DA, Nunn AI. Influence of initial drug resistance on the response to short-course chemotherapy on pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423-430.
59. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 2002, 46:119-124.
60. Sahm D, Peterson D, Critchley I, Thronsberry C. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000, 44:2521-2524.
61. Sahm D, Karlowsky J, Kelly L, Critchley I, Jones M, Thornsberry C, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001, 45: 1037-1042.
62. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996, 38 (Suppl. A): 117-132.
63. Johnson AP. Antibiotic resistance among clinically important Gram-positive bacteria in the UK. J Hosp Infect 1998, 40:17-26.
64. Drlica K. A strategy for fighting antibiotic resistance. ASM News 2001, 67:27-33.
65. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-12.
66. Preston S, Drusano G, Berman A, Fowler C, Chow A, Dornseif B, et al. Pharmacodyamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279:125-129.
67. Drusano G. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Inf Dis 2003, 36 (Suppl 1):S42-S50.